Genoa Pharmaceuticals, McMaster University report additional benefits of...
Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of...
View ArticlePFF Patient Communication Center: The destination for latest disease...
The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has...
View ArticleFirst Edition: May 19, 2014
Today's headlines include a report about federal health care subsidies and an update on states small business health exchanges.
View ArticleResearchers identify drugs to slow progression of idiopathic pulmonary fibrosis
Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently...
View ArticleFDA grants orphan-drug designation to Genoa's pirfenidone for treatment of...
Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of...
View ArticleViewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to...
You're looking at the biggest story involving the federal budget and a crucial one for the future of the American economy. Every year for the last six years in a row, the Congressional Budget Office...
View Article2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet...
This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only...
View ArticlePulmospheres could serve as personalized, predictive model for assessing...
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary...
View ArticleLung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis
Developing new medicines to treat pulmonary fibrosis, one of the most common and serious forms of lung disease, is not easy.
View ArticleResearchers identify culprit that spurs damaging inflammation following heart...
Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead...
View ArticleNew lung tissue-on-a-chip system offers rapid testing of potential...
Pulmonary fibrosis is one of the most common and serious types of lung disease. Now NIBIB-funded researchers have developed an in vitro lung tissue-on-a-chip system that mimics lung fibrosis, offering...
View ArticleCost of ‘repurposing’ existing drugs to treat COVID-19
The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for...
View ArticlePowerful treatment for IPF stops dangerous scar formation in mouse lungs
A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the...
View ArticlePirfenidone significantly reduces a marker of heart muscle scarring
Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who...
View ArticleY chromosome loss in men can lead to deadly heart failure, research shows
The loss of the male sex chromosome as many men age causes the heart muscle to scar and can lead to deadly heart failure, new research from the University of Virginia School of Medicine shows.
View ArticleAnti-fibrotics found to be safe, effective for interstitial lung disease in...
For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).
View Article3D cell culture system tests how inhibiting fibroblast activities can help...
Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.
View ArticleUnderstanding post-COVID interstitial lung disease: Causes, treatment options
After being hospitalized for three months with COVID-19 and double pneumonia in 2020, Houston police officer Hito Bazan awoke one morning to discover that he couldn't talk, eat, walk, or most...
View Article3D-printed vaginal ovules offer promising treatment for endometriosis
3D-printed vaginal ovules offer controlled release and targeted treatment, showing promise for conditions like endometriosis.
View ArticleHuman senescent fibroblasts trigger fibrogenic reaction in the lungs of...
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, "Human senescent fibroblasts...
View Article